Technology | Nuclear Imaging | July 16, 2018

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software

New features bring high-level clinical capabilities to PET imaging in oncology and neurology

Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software

July 16, 2018 — At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia, Siemens Healthineers announced U.S. Food and Drug Administration (FDA) clearance of syngo.via VB30 for Molecular Imaging (MI). The latest version of the company’s intelligent imaging software, syngo.via VB30 for MI has new features designed to bring advanced clinical capabilities to positron emission tomography/computed tomography (PET/CT) imaging in oncology and neurology.

syngo.via VB30 for MI automatically calculates a patient’s Deauville score – an internationally recognized scoring system used by oncologists in the initial staging and evaluation of therapeutic response for patients with Hodgkin lymphoma and most types of non-Hodgkin lymphoma. By avoiding the laborious, time-consuming task of manual Deauville score determination, clinicians can save time and increase efficiency.

Also, syngo.via VB30 for MI offers a unique platform for viewing and interpreting parametric PET images. Using dedicated layouts that permit simultaneous visualization of the summed Standard Uptake Values (SUV), the metabolic rate of glucose (MRFDG), and distribution volume images, readers can easily quantify the FDG uptake of these parametric indices.

Additionally, the new platform’s PET/CT and single photon emission computed tomography (SPECT)/CT hybrid VRT (volume-rendering technique) feature enables 3-D visualization of the disease state in a single image. This feature permits user-friendly interpretation of the cancer relative to anatomical landmarks.

Finally, syngo.via VB30 for MI offers improvements for the quantitative analysis of various neurological conditions via either self-created or widely used databases for various disease states. The assessment of striatal activity in the evaluation of Parkinson’s disease, hypometabolic seizure foci in the evaluation of epilepsy, and amyloid plaque burden in the evaluation of dementia can be conducted quantitatively. This ability provides more information to the reading physician to help increase diagnostic confidence.

For more information: www.usa.healthcare.siemens.com

Related Content

Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
SimonMed Deploys ClearRead CT Enterprise Wide
News | Computer-Aided Detection Software | September 17, 2018
September 17, 2018 — National outpatient physician radiology group SimonMed Imaging has selected Riverain Technologie
SmartCurve technology, a revolutionary breast imaging technology designed specifically for the curvature of the female breast to provide every woman with a more comfortable and accurate mammogram.
News | Mammography | September 14, 2018
Solis Mammography declared September Breast Wellness Month a
At RSNA 2018, radiology professionals will discover intelligent radiography powered by MUSICA, at Agfa's booth.

At RSNA 2018, radiology professionals will discover intelligent radiography powered by MUSICA, at Agfa's booth.

News | Digital Radiography (DR) | September 13, 2018
At RSNA 2018, radiology professionals will discover intelligent
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Lightvision near-infrared fluorescence imaging system
News | Women's Health | September 11, 2018
Shimadzu Corp.
Veye Chest version 2
News | Lung Cancer | September 11, 2018
Aidence, an Amsterdam-based medical AI company, announced that Veye Chest version 2, a class IIa medical device, has
Sponsored Content | Whitepapers | Radiation Dose Management | September 10, 2018
It’s crucial for medical professionals to understand the radiation risk/ benefit balance of diagnostic imaging system